A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02574078
Completed
The purpose of this study is to determine whether nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2021
Locations: Texas Oncology-Abilene, Abilene, Texas +31 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma
NCT02468557
Terminated
The primary objective of this study is to evaluate the safety of single agent idelalisib and to evaluate safety and define the maximum tolerated dose (MTD) of idelalisib in combination with chemotherapy in adults with metastatic pancreatic ductal adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2021
Locations: Mary Crowley Medical Research Center, Dallas, Texas
Conditions: Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Register for Updates
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
NCT02264990
Completed
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/08/2021
Locations: UT Southwestern Medical Center /ID# 130236, Dallas, Texas +1 locations
Conditions: Non-squamous Non-small Cell Lung Cancer
Register for Updates
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
NCT02032277
Completed
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
01/15/2021
Locations: Texas Oncology - Bedford /ID# 126135, Bedford, Texas +7 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer
NCT00662597
Terminated
The purpose of this study is to determine if adding ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with advanced lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/16/2020
Locations: Texas Oncology Cancer Center of the High Plains, Amarillo, Texas +12 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.
NCT00269828
Terminated
This is a randomized, open-label, multinational, phase III study in women with histologically- or cytologically-confirmed advanced NSCLC who are chemotherapy naïve and have PS 2. Study drug will be administered on day 1 of each 21 day cycle
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/23/2020
Locations: Mary Crowley Medical Research Center, Dallas, Texas +1 locations
Conditions: NSCLC
Register for Updates
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
NCT02106546
Completed
The purpose of this study is to evaluate the safety and efficacy of the addition of veliparib plus carboplatin and paclitaxel versus the addition of placebo plus carboplatin and paclitaxel in adults with advanced or metastatic squamous non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
11/13/2020
Locations: Texas Oncology - Austin Midtown /ID# 127477, Austin, Texas +7 locations
Conditions: Squamous Non-Small Cell Lung Cancer
Register for Updates
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
NCT02625623
Completed
The purpose of this study was to demonstrate superiority of treatment with avelumab plus best supportive care (BSC) versus physician's choice (chosen from a pre-specified list of therapeutic options) plus BSC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2020
Locations: Texas Oncology Bedford 1609 Hospital Parkway, Bedford, Texas +7 locations
Conditions: Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
Register for Updates
CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL
NCT00576225
Withdrawn
This study is designed to test whether CT-2103/carboplatin provides improved overall survival compared to paclitaxel/carboplatin in women with NSCLC who have estradiol levels \>30 pg/ml.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/14/2020
Locations: Southwest Regional Cancer Center, Austin, Texas +2 locations
Conditions: NSCLC
Register for Updates
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
NCT01745367
Terminated
This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study for subjects with locally recurrent or metastatic triple negative breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/05/2020
Locations: Not set, Dallas, Texas +1 locations
Conditions: Triple Negative Breast Cancer
Register for Updates
Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00551733
Terminated
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, and paclitaxel poliglumex, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving carboplatin together with paclitaxel poliglumex is more effective than giving carboplatin together with paclitaxel in treating non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel poliglume... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/02/2020
Locations: Southwest Regional Cancer Center - Central, Austin, Texas +2 locations
Conditions: Lung Cancer
Register for Updates
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
NCT00622466
Terminated
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving sorafenib together with paclitaxel and to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2020
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Breast Cancer
Register for Updates